Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences (NBIX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 8:15 a.m. Pacific Time.
Chief Executive Officer Kyle Gano will deliver the company's presentation, which will be accessible through a live webcast on the company's website under the Investors section at www.neurocrine.com. For those unable to attend the live event, a replay will be made available approximately one hour after the presentation concludes and will remain accessible for about one month.
Neurocrine Biosciences (NBIX) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare a San Francisco. La presentazione è prevista per lunedì 13 gennaio 2025, alle 8:15 ora del Pacifico.
Il Direttore Esecutivo Kyle Gano presenterà l'azienda, e la presentazione sarà accessibile tramite un webcast dal vivo sul sito web della società nella sezione Investitori su www.neurocrine.com. Per chi non potrà partecipare all'evento dal vivo, sarà disponibile una registrazione circa un'ora dopo la conclusione della presentazione e resterà accessibile per circa un mese.
Neurocrine Biosciences (NBIX) ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare en San Francisco. La presentación está programada para el lunes 13 de enero de 2025, a las 8:15 a.m. hora del Pacífico.
El Director Ejecutivo Kyle Gano realizará la presentación de la compañía, que será accesible a través de una transmisión en vivo en el sitio web de la compañía en la sección de Inversores en www.neurocrine.com. Para quienes no puedan asistir al evento en vivo, se hará disponible una repetición aproximadamente una hora después de que concluye la presentación y se mantendrá accesible durante aproximadamente un mes.
Neurocrine Biosciences (NBIX)는 샌프란시스코에서 열리는 제43회 JP모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 발표는 2025년 1월 13일 월요일, 태평양 표준시 기준 오전 8시 15분에 예정되어 있습니다.
CEO Kyle Gano가 회사 발표를 진행하며, 발표는 회사 웹사이트의 투자자 섹션인 www.neurocrine.com에서 실시간 웹캐스트를 통해 청취할 수 있습니다. 실시간 이벤트에 참석할 수 없는 분들을 위해 발표 종료 후 약 한 시간 후에 다시 보기 서비스가 제공되며, 약 한 달 동안 접근 가능합니다.
Neurocrine Biosciences (NBIX) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco. La présentation est prévue pour le lundi 13 janvier 2025 à 8h15, heure du Pacifique.
Le directeur général Kyle Gano présentera l'entreprise, et la présentation sera accessible via un webcast en direct sur le site internet de l'entreprise dans la section Investisseurs à www.neurocrine.com. Pour ceux qui ne pourront pas assister à l'événement en direct, un replay sera disponible environ une heure après la fin de la présentation et restera accessible pendant environ un mois.
Neurocrine Biosciences (NBIX) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco bekannt gegeben. Die Präsentation ist für Montag, den 13. Januar 2025, um 8:15 Uhr Pazifischer Zeit angesetzt.
Der Geschäftsführer Kyle Gano wird die Unternehmenspräsentation halten, die über einen Live-Webcast auf der Unternehmenswebsite im Bereich Investoren unter www.neurocrine.com zugänglich sein wird. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird eine Wiederholung etwa eine Stunde nach der Abschluss der Präsentation verfügbar sein und für etwa einen Monat zugänglich bleiben.
- None.
- None.
The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter) and Facebook. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302343441.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch NBIX's presentation at the J.P. Morgan Healthcare Conference?
How long will NBIX's J.P. Morgan Healthcare Conference presentation replay be available?
Who will be presenting for NBIX at the 2025 J.P. Morgan Healthcare Conference?
When will the replay of NBIX's J.P. Morgan Healthcare Conference presentation become available?
